New Zealand markets closed

Hestia Insight Inc. (HSTA)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.17700.0000 (0.00%)
At close: 01:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.1770
Open0.1602
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.1770 - 0.1770
52-week range0.0300 - 1.0200
Volume4,500
Avg. volume2,108
Market cap4.945M
Beta (5Y monthly)0.49
PE ratio (TTM)N/A
EPS (TTM)-0.6950
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Hestia Insight Inc. Subsidiary Enters Into Corporate Advisory Agreement With Aquiva Medical Inc.

    LAS VEGAS, NV, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that through its wholly owned subsidiary, Hestia Investments Inc., the Company entered

  • GlobeNewswire

    Hestia Insight Inc. Unveils Innovative Marketing Plan to Assist Emerging Companies

    LAS VEGAS, NV, Dec. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) ("Hestia Insight" and the “Company”), a company focused on the development and operation of novel technologies and providing marketing, management, business, and capital markets advisory services to its clients, today announced the launch of its new marketing plan - a strategic initiative designed to empower emerging growth companies by integrating professional expertise, top-tier talent, and AI

  • GlobeNewswire

    Hestia Insight Inc. Announces Upcoming Launch of AI-Powered IR Website Platform to Assist Start-Ups, Small and Medium Sized Companies

    NEW YORK, NY, Aug. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, and providing marketing, management, business, and capital markets advisory services to its clients within the healthcare and biotech sectors, today announced that in September 2023, its wholly owned subsidiary, Hestia Investments Inc. (“Hestia Inve